|
1
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sánchez de Cos J, Sojo González MA,
Montero MV, et al: Non-small cell lung cancer and silent brain
metastasis. Survival and prognostic factors. Lung Cancer.
63:140–145. 2009. View Article : Google Scholar
|
|
3
|
Chen CL, Ip SM, Cheng D, Wong LC and Ngan
HY: Loss of imprinting of the IGF-II and H19 genes in epithelial
ovarian cancer. Clin Cancer Res. 6:474–479. 2000.PubMed/NCBI
|
|
4
|
Yang F, Zhang L, Huo XS, et al: Long
noncoding RNA high expression in hepatocellular carcinoma
facilitates tumor growth through enhancer of zeste homolog 2 in
humans. Hepatology. 54:1679–1689. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lai MC, Yang Z, Zhou L, et al: Long
non-coding RNA MALAT-1 overexpression predicts tumor recurrence of
hepatocellular carcinoma after liver transplantation. Med Oncol.
29:1810–1816. 2012. View Article : Google Scholar
|
|
6
|
Tsang WP and Kwok TT: Riboregulator H19
induction of MDR1-associated drug resistance in human
hepatocellular carcinoma cells. Oncogene. 26:4877–4881. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fan Y, Shen B, Tan M, et al: Long
non-coding RNA UCA1 increases chemoresistance of bladder cancer
cells by regulating Wnt signaling. FEBS J. 281:1750–1758. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jiang M, Huang O, Xie Z, et al: A novel
long non-coding RNA-ARA: Adriamycin resistance-associated. Biochem
Pharmacol. 87:254–283. 2014. View Article : Google Scholar
|
|
9
|
Gejman R, Batista DL, Zhong Y, et al:
Selective loss of MEG3 expression and intergenic differentially
methylated region hypermethylation in the MEG3/DLK1 locus in human
clinically nonfunctioning pituitary adenomas. J Clin Endocrinol
Metab. 93:4119–4125. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sun M, Xia R, Jin F, et al: Downregulated
long noncoding RNA MEG3 is associated with poor prognosis and
promotes cell proliferation in gastric cancer. Tumour Biol.
35:1065–1073. 2014. View Article : Google Scholar
|
|
11
|
Ying L, Huang Y, Chen H, et al:
Downregulated MEG3 activates autophagy and increases cell
proliferation in bladder cancer. Mol Biosyst. 9:407–411. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang P, Ren Z and Sun P: Overexpression of
the long non-coding RNA MEG3 impairs in vitro glioma cell
proliferation. J Cell Biochem. 113:1868–1874. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Qin R, Chen Z, Ding Y, Hao J, Hu J and Guo
F: Long non-coding RNA MEG3 inhibits the proliferation of cervical
carcinoma cells through the induction of cell cycle arrest and
apoptosis. Neoplasma. 60:486–492. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhao X, Xu Z, Wang Z, et al: RNA silencing
of integrin-linked kinase increases the sensitivity of the A549
lung cancer cell line to cisplatin and promotes its apoptosis. Mol
Med Rep. 12:960–966. 2015.PubMed/NCBI
|
|
15
|
Stewart DJ: Wnt signaling pathway in
non-small cell lung cancer. J Natl Cancer Inst. 106:djt3562014.
View Article : Google Scholar
|
|
16
|
Ward JH: NCCN Guidelines and the
International Community. J Natl Compr Canc Netw. 9:133–134.
2011.PubMed/NCBI
|
|
17
|
Zhou Y, Zhong Y, Wang Y, et al: Activation
of p53 by MEG3 non-coding RNA. J Biol Chem. 282:24731–24742. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Miao W, Liu X, Wang H, et al: p53
upregulated modulator of apoptosis sensitizes drug-resistant U251
glioblastoma stem cells to temozolomide through enhanced apoptosis.
Mol Med Rep. 11:4165–4173. 2015.PubMed/NCBI
|
|
19
|
Sadot E, Geiger B, Oren M and Ben-Ze'ev A:
Down-regulation of beta-catenin by activated p53. Mol Cell Biol.
21:6768–6781. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wu MY, Xie X, Xu ZK, et al: PP2A
inhibitors suppress migration and growth of PANC-1 pancreatic
cancer cells through inhibition on the Wnt/beta-catenin pathway by
phosphorylation and degradation of β-catenin. Oncol Rep.
32:513–522. 2014.PubMed/NCBI
|
|
21
|
Gao Y, Liu Z, Zhang X, et al: Inhibition
of cytoplasmic GSK-3β increases cisplatin resistance through
activation of Wnt/β-catenin signaling in A549/DDP cells. Cancer
Lett. 336:231–239. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ren S, Liu Y, Xu W, et al: Long noncoding
RNA MALAT-1 is a new potential therapeutic target for castration
resistant prostate cancer. J Urol. 190:2278–2287. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Schmidt LH, Spieker T, Koschmieder S, et
al: The long noncoding MALAT-1 RNA indicates a poor prognosis in
non-small cell lung cancer and induces migration and tumor growth.
J Thorac Oncol. 6:1984–1992. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xi YN, Xin XY and Ye HM: Effects of HMGA2
on malignant degree, invasion, metastasis, proliferation and
cellular morphology of ovarian cancer cells. Asian Pac J Trop Med.
7:289–292. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Prensner JR, Iyer MK, Sahu A, et al: The
long noncoding RNA SChLAP1 promotes aggressive prostate cancer and
antagonizes the SWI/SNF complex. Nat Genet. 45:1392–1398. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yang F, Huo XS, Yuan SX, et al: Repression
of the long noncoding RNA-LET by histone deacetylase 3 contributes
to hypoxia-mediated metastasis. Mol Cell. 49:1083–1096. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chang A: Chemotherapy, chemoresistance and
the changing treatment landscape for NSCLC. Lung Cancer. 71:3–10.
2011. View Article : Google Scholar
|
|
28
|
Strathdee G: Epigenetic markers and
response to chemotherapy in cancer. Dis Markers. 23:43–49. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Liu Z, Sun M, Lu K, et al: The long
noncoding RNA HOTAIR contributes to cisplatin resistance of human
lung adenocarcinoma cells via downregualtion of p21 (WAF1/CIP1)
expression. PloS One. 8:e772932013. View Article : Google Scholar
|
|
30
|
Braconi C, Kogure T, Valeri N, et al:
microRNA-29 can regulate expression of the long non-coding RNA gene
MEG3 in hepatocellular cancer. Oncogene. 30:4750–4756. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Butz H and Patocs A: Pituitary
tumorigenesis: role of regulation of Wee1 kinase by microRNAs.
Tumors of the Central Nervous System. Hayat M: 10. Springer;
Dordrecht: pp. 141–150. 2013
|
|
32
|
McCubrey JA, Steelman LS, Abrams SL, et
al: Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in
malignant transformation and drug resistance. Adv Enzyme Regul.
46:249–279. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bouwman P and Jonkers J: The effects of
deregulated DNA damage signalling on cancer chemotherapy response
and resistance. Nat Rev Cancer. 12:587–598. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Cui J, Jiang W, Wang S, Wang L and Xie K:
Role of Wnt/β-catenin signaling in drug resistance of pancreatic
cancer. Curr Pharm Des. 18:2464–2471. 2012. View Article : Google Scholar
|
|
35
|
Yang D, Welm A and Bishop JM: Cell
division and cell survival in the absence of survivin. Proc Natl
Acad Sci USA. 101:15100–15105. 2004. View Article : Google Scholar : PubMed/NCBI
|
